News | Artificial Intelligence | November 07, 2019

Mirada Medical Announces New Wave of Global Installations of DLCExpert

Announcement builds on Mirada Medical’s FDA clearance of DLCExpert in 2018, giving the deep learning autocontouring system one year of clinically approved experience

Bladder Abdomen Pelvis image with DLCExpert

November 7, 2019 — Mirada Medical, a global leader in artificial intelligence (AI) software for the treatment of cancer, announced further global installations of DLCExpert, the world’s first commercially available AI-powered autocontouring software for cancer treatment planning and the only system with over one year of clinically proven use.

Mirada’s advanced software products targeting cancer care are in daily clinical use at over 1,400 hospitals worldwide and its breakthrough DLCExpert AI system has been recently deployed at multiple global centers of clinical excellence including Moffitt Cancer Center, Mayo Clinic, UMC Groningen, and The Christie NHS Foundation Trust.

The company has today announced further installations at leading cancer centers in the United States and Europe including Northwestern Hospital (IL), City of Hope (CA), CHU Liège, and Royal Surrey NHS Foundation Trust.

Amato J. Giaccia, M.D., director of the Institute of Radiation Oncology at Oxford University and  Chairperson of the Mirada Medical Strategic Advisory Board, said: “With Mirada Medical’s  deployments of DLCExpert now benefiting cancer patients globally and on a daily basis , I couldn’t be more excited to be a part of this exciting company as Chairman of the Strategic Medical Advisory Board.”

Giaccia continued, “I believe that automated contouring of organs at risk (OARs) using AI is revolutionizing the radiotherapy planning process. Not only can AI free up doctors’ time, which is a huge benefit for patients, but it may also enable better outcomes.

“This is not just about producing faster workflows, it’s also about the overall quality of treatment plans, as AI will be able to help identify normal tissue and preserve at risk tissue. This, in turn, will help deliver greater personalised care, while potentially contributing to improved outcomes.”

These milestone achievements track alongside a continually growing body of clinical evidence, produced in partnership with global academic medical partners, that underlines the real-word benefit obtained by clinics who have deployed the world-first deep learning autocontouring system, Mirada’s DLCExpert. In particular, multiple published clinical studies provide robust evidence which confirms that software generated contours, reviewed and refined by clinicians, represent a viable strategy for reducing contouring time while also reinforcing compliance with established clinical standards. Research published by the American Association of Physicists in medicine has indicated time savings of up to 77 percent for some organs, resulting from editing software generated contours compared to the standard clinical workflow.

Charlotte Brouwer, medical physicist at the Department of Radiation Oncology, University Medical Center Groningen, said: “The collaboration between UMC Groningen and Mirada Medical has produced autocontouring models that encode according to consensus guidelines, established by an international panel of experts for organs at risk. These DLCExpert models are now deployed in our routine clinical workflows, forming a key part of our treatment planning for all patients with cancers in the head and neck or prostate regions.

“Thanks to DLCExpert, we now enjoy measurable and consistent time-savings, which we expect to translate to other institutions," she continued. "Perhaps the clearest indications of their clinical acceptance were the loud objections of our RT planning team when the models were briefly unavailable during routine maintenance!”

Mirada Medical CEO Hugh Bettesworth said: “I am delighted that Mirada’s technology is being deployed so widely and that patients are benefitting from it every day. We hear a lot of talk about bringing artificial intelligence to medicine - I am immensely proud that it is Mirada’s brilliant team of scientists and engineers who have worked with our customers, our clinical advisors, and the regulators in the USA and Europe, and have delivered every-patient clinical advances for cancer treatment planning using artificial intelligence.”

For more information: www.axicom.com

Related content:

VIDEO: Artificial Intelligence Automatic Contouring and Segmentation For Radiotherapy

Mirada Medical Showcases DLCExpert AI-Based Radiotherapy Contouring Software at ASTRO 2018

Related Content

AI vendor Infravision's InferRead CT Pneumonia software uses artificial intelligence-assisted diagnosis tp improve the overall efficiency of the radiology department. It is being delayed in China as a high sensitivity detection aid for novel coronavirus pneumonia (COVID-19). #COVID-19 #COVID19 #Coronavirus #2019-nCoV

AI vendor Infravision's InferRead CT Pneumonia software uses artificial intelligence-assisted diagnosis tp improve the overall efficiency of the radiology department. It is being delayed in China as a high sensitivity detection aid for novel coronavirus pneumonia (COVID-19).

Feature | Coronavirus (COVID-19) | February 28, 2020
February 28, 2020 — New healthcare technologies are being implemented in the fight against the novel coronavirus (COV
 LucidHealth, a physician-owned and led radiology company, announced today that it is using an AI-powered diagnostic aid from leading AI vendor Aidoc to help prioritize and expedite treatment to patients with critical, life-threatening conditions
News | Artificial Intelligence | February 28, 2020
February 28, 2020 — LucidHealth, a physician-owned and led r
Qure.ai, a leading healthcare AI startup
News | Artificial Intelligence | February 27, 2020
February 27, 2020 — Qure.ai, a leading healthcare AI startup has ann
Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
Sponsored Content | Videos | Artificial Intelligence | February 21, 2020
In Artificial Intelligence at RSNA 2019, ITN Contributing Editor Greg Freiherr offers an overview of artificial intel
Sponsored Content | Videos | Enterprise Imaging | February 21, 2020
In Enterprise Imaging at RSNA 2019, ITN Contributing Editor Greg Freiherr offers an overvie
An example of the MRI scans showing long-term and short-term survival indications. #MRI

An example of the MRI scans showing long-term and short-term survival indications. Image courtesy of Case Western Reserve University

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — ...
Altamont’s zero-footprint solution, CaptureWare, allows Mach7’s Enterprise Imaging Platform (EIP) to ingest more DICOM and/or non-DICOM data from various sources in a facility
News | PACS | February 20, 2020
February 20, 2020 — Mach7 announced its partnership with Altamont
Chest CT imaging of patient. #coronavirus #nCoV2019 #2019nCoV #COVID19

Examples of typical chest CT findings compatible with COVID-19 pneumonia in patients with epidemiological and clinical presentation suspicious for COVID-19 infection. This image is part of the original research, Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR, published Feb. 19, 2020, in Radiology Online.

News | Computed Tomography (CT) | February 19, 2020
February 19, 2020 — In new research
Sponsored Content | Videos | Enterprise Imaging | February 19, 2020
Bill Lacy, vice president, Medical Informatics at FUJIFILM Medic...